Our Story

At Reata, our principles guide us.

mountain hirez

Since its founding in 2002, Reata has been leading the dawn of a new era in pharmaceutical approaches for the treatment of serious and life-threatening diseases.

We are dedicated to understanding the biology that underlies disease. We strive to understand complex, interconnected molecular pathways with significant potential to impact human pathophysiology, and apply our deep understanding of the cellular response to injury to develop innovative medicines.

Our scientific mission is to identify, develop, and commercialize small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the cellular response to injury.

What we do

Our investigational Nrf2 activators, including omaveloxolone, bardoxolone methyl, and next generation molecules, modulate genes involved in cellular metabolism and mitochondrial function to regulate the cellular inflammatory response (1-4). We are developing omaveloxolone and bardoxolone methyl for treatment of Friedreich's ataxia and chronic kidney disease, respectively. Our novel small molecule inhibitor of HSP90 is in development for treatment of neurological diseases.

Our robust clinical and preclinical development programs have promise as potential treatments across a range of diseases with few or no approved therapies.

Beyond our current technologies, we actively pursue scientific discoveries to advance medicine. We value strategic opportunities that arise through partnerships with premier academic institutions and research companies.

At Reata, we understand the importance of listening to the voices of patients living with life-threatening diseases. Our partnerships with patient advocacy groups help us gain a deeper understanding of the diseases we explore. Their experience inspires us to leave no stone unturned in our quest to develop safe and effective therapies.

bench

Who we are

We are rooted in the Dallas-Fort Worth area. We are proud trailblazers that led the way in the growth and expansion of the pharmaceutical and biotechnology industry in the region. We are tenacious and resilient in the face of adversity, hardworking, and committed to our goals of having a meaningful impact on the lives of patients with severe life-threatening diseases. As regional leaders, we value our peers and academic partners and are committed to continue building and supporting the industry in the region.

References

  1. Yamamoto, M., Kensler, T. W., and Motohashi, H. (2018) The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev 98, 1169-1203
  2. Hayes, J. D., and Dinkova-Kostova, A. T. (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci 39, 199-218
  3. Holmstrom, K. M., Kostov, R. V., and Dinkova-Kostova, A. T. (2016) The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol 1, 80-91
  4. Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., and Yamamoto, M. (2016) Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7, 11624


back to top
Hamilton Pool